About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

Our lead investigational product candidate, AFREZZA®
(pronounced uh-FREZZ-uh)
is a novel, ultra rapid-acting mealtime insulin therapy being studied for the treatment of adult patients with Type 1 and Type 2 diabetes mellitus for the control of hyperglycemia. More >

 

Spotlight

MannKind has completed Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes (Affinity 1) and in Patients with Type 2 Diabetes (Affinity 2).

Read the latest press release here.

News & Events

   
Jun 17, 2013 MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes More >
Jun 11, 2013 MannKind to Present at Wells Fargo Securities Research & Economics 2013 Healthcare... More >
May 31, 2013 MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes More >